| Author/year | Centre | Period | Design |
Chemotherapy | EPP | Rx | F/U |
| Schipper et al., 2008 [20] | Mayo clinic | 1985–2003 | Retrospective review of prospective database | Unknown | 77 | Unknown | 5 years | Luckraz et al. 2010 [21] | University Hospital of Wales, UK | 1980–2010 | Retrospective review of prospective database | All referred | 49 of which 15 TMT | All referred | 5 years | Flores et al., 2008 [22] | 3 cancer centres in USA | 1990–2006 | Retrospective review | Clinical trial dependent | 385 total | Clinical trial dependent | 5 years | Okada et al., 2008 [23] | Japan single centre | 1986–2006 | Retrospective review | 5 | 31 | 5 | 5 years | Aziz et al., 2002 [15] | Scotland single centre | 1989–1998 | Retrospective review | 51 | 64 | 51 | 5 years | Lang-Lazdunski et al., 2011 [28] | Guy’s and St Thomas, UK | 2004–2011 | Prospective observational | 22 | 22 | 17 | 5 years | Krug et al., 2009 [30] | Multicentre, US | 2003–2006 | Randomised trial | 77 neoadjuvant | 54 | 44 | 5 years | Buduhan et al., 2009 [31] | Washington, USA | 1997–2008 | Retrospective | 46 neoadjuvant | 46 | 44 | 6 years | De Perrot et al., 2009 [32] | Single centre, Canada | 2001–2007 | Retrospective | 60 neoadjuvant | 45 | 30 | 5 years | Weder et al., 2007 [33] | Multicentre, Europe |
2000–2003 | Prospective | 58 neoadjuvant | 45 | 36 | 5 years | Rea et al., 2013 [34] | 4 centres, Italy | 2005–2010 | Retrospective | 52 neoadjuvant | 41 | 32 | 2 years | Sugarbaker et al., 1999 [29] | 3 centres, USA | 1980–1997 | Retrospective | 183 adjuvant | 183 | 183 | 5 years | Van Schil et al., 2010 [35] | 11 centres, Europe | 2005–2007 | Prospective trial | 58 neoadjuvant | 42 | 37 | 3 years | Treasure et al., 2011 [16] | 12 centres UK | 2005–2008 | RCT | 24 | 19 | 8 | 2 years | Rena and Casadio 2012 [25] | Single centre, Italy | 1998–2009 | Retrospective | 40 | 40 | 40 | 3 years | Tonoli et al., 2011 [36] | 3 centres, Italy | 2005–2010 | Retrospective | 48 | 56 | 56 | 6 years |
|
|